Abstract 5633: BreastDefend suppresses growth and breast-to-lung cancer metastasis in an orthotopic model of human breast cancer

• Published in: Cancer research (Chicago, Ill.) Vol. 72; no. 8_Supplement; p. 5633
• Main Authors: Jiang, Jiahua, Thyagarajan-Sahu, Anita, Loganathan, Jagadish, Eliaz, Isaac, Terry, Colin, Sandusky, George, Sliva, Daniel
• Format: Journal Article
• Language: English
• Published: 15.04.2012
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/1538-7445.AM2012-5633

Abstract We have recently demonstrated that a natural dietary supplement BreastDefend (BD), which contains extracts from medicinal mushrooms (Coriolus versicolor, Ganoderma lucidum, Phellinus linteus), medicinal herbs (Scutellaria barbata, Astragalus membranaceus, Curcuma longa), and purified biologically active nutritional compounds (diindolylmethane and quercetin), inhibits proliferation and metastatic behavior of invasive human breast cancer cells MDA-MB-231 in vitro. In the present study we have evaluated whether BD suppresses growth and breast-to lung cancer metastasis in an orthotopic model of human breast cancer cells implanted in mice. An oral application of BD (100 mg/kg of body weight for 4 weeks) by intragastrical gavage did not affect body weight or activity of liver enzymes and did not show any sign of toxicity in liver spleen, kidney, lung and heart tissues in mice. Moreover, BD significantly decreased the change in tumor volume over time when compared to the control group (p=0.002). BD treatment also markedly decreased the incidence of breast-to-lung cancer metastasis from 67 % (control) to 20% (BD) (p<0.05) and number of metastasis from 2.8 [0.0, 48.0] in the control group to 0.0 [0.0, 14.2] in the BD treatment group (p<0.05). Finally, anti-metastatic activity of BD in vivo was further confirmed by the down-regulation of expression of PLAU (urokinase plasminogen activator, uPA) and CXCR4 (C-X-C chemokine receptor-4) genes in breast tumors. In conclusion, BD may be considered as a biological therapeutic agent against invasive breast cancers. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5633. doi:1538-7445.AM2012-5633